Campbell Neurosciences Press Releases

trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction

Campbell Neurosciences Division Expands its "Regenerative Psychiatry" Approach to Address the $179 Billion Dollar Prescription Opioid Epidemic


https://www.prnewswire.com/news-release ... 96771.html


Dec 21, 2020, 09:00 ET


OCEANSIDE, Calif., Dec. 21, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a patent covering utilization of its NeuroLeukin™ product for altering molecular pathways associated with opioid addiction. In a series of animal experiments NeuroLeukin™ was demonstrated to reduce activation of TLR-4, which is one of the major innate immune pathways associated with opioid tolerance and addiction1.

It is estimated that the current opioid use epidemic costs the health care system approximately $179 Billion annually2. Campbell Neurosciences, the Company's Division focused on suicide prevention has previously filed intellectual property on utilizing NeuroLeukin™ to reduce suicidal ideations.

"The common biochemical pathways of opioid addiction and suicidal ideation should be no surprise given the inherent relationship between these two conditions," said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "Currently we have 2 clinical trials on the Federal ClinicalTrials.gov website dealing with immunological quantification of psychiatric disorders: suicide and gambling. We are excited to take NeuroLeukin™ into the clinic, which to my knowledge represents the first immunotherapeutic approach for opioid addiction."

"Immunotherapy, which at one point was considered on the fringe of medicine, has blossomed into what is expected to be a 126-billion-dollar annual market in 20263, given its recent successes in the treatment of cancer," said Famela Ramos, Vice President of Business Development and co-inventor of the patent. "We are excited to position ourselves as the potential leaders in applying immunotherapy to mental disorders, an approach that we like to call "regenerative psychiatry."

"Having seen many close friends of mine suffer the horrible effects of opioid addiction, I am proud to be co-inventor on an approach which has the potential to revolutionize the way drug addiction is seen by the medical community," said Wais Kaihani, consultant to the Company.

"I am thankful for our internationally renowned scientific advisory board, which is comprised of immunologists and neurobiologists, that have stimulated our Company to enter such an unexplored space in which very little therapeutic interventions exist," said Timothy Dixon, President and CEO of the Company and co-inventor. "We are 100% dedicated to ending the opioid crisis or catalyzing development of novel approaches to accelerate an end to this tragic and avoidable loss of life."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com

1 Discovery of a Novel Site of Opioid Action at the Innate Immune Pattern-Recognition Receptor TLR4 and its Role in Addiction - ScienceDirect
2 What Are The Real Costs Of The Opioid Epidemic? : Shots - Health News : NPR
3 Cancer Immunotherapy Market Worth $126.9 Billion By 2026 (grandviewresearch.com)

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company

Campbell Neurosciences to License Key Intellectual Property Assets as Clinical Trials of Campbell Score and Kaihani Score are Ongoing


https://www.prnewswire.com/news-release ... 99636.html



OCEANSIDE, Calif., Dec. 31, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the launching of Campbell Neurosciences Inc as a partially owned spin-off from the Company. The new corporation will be led by Ms. Kalina O'Connor as President and Chief Executive Officer, Dr. James Veltmeyer as Chief Medical Officer, and Ms. Jona Barnes as Chief Financial Officer.

Campbell Neurosciences Inc has signed license agreements with Therapeutic Solutions International for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are:

1. 63/128759 Immunotherapy for Opioid Addiction
2. 63/122862 Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches
3. 63/105964 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia
4. 17/030416 Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention
5. 63/077723 Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide
6. 63/071381 Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline
7. 63/068388 Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment
8. 63/061202 Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions
9. 63/057315 Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof

Additionally, Campbell Neurosciences Inc. has entered into purchase agreements with Therapeutic Solutions International ensuring a continued supply, at a discounted rate, of nutraceuticals which are being explored for antiinflammation/suicide prevention activity.

"I am honored that the Board of Therapeutic Solutions International has agreed to spin off the Campbell Neurosciences Division as an independent entity," said Kalina O'Connor, Chief Executive Officer of Campbell Neurosciences Inc. "By leveraging the unique relationship between immunology, neurosciences and regenerative medicine, we aim to position ourselves as leaders in establishing a scientific and quantifiable basis to the practice of regenerative psychiatry."

"Having collaborated with Ms. O'Connor in our work at Therapeutic Solutions International, I am pleased to be the Chief Medical Officer of Campbell Neurosciences, a company dedicated to preventing suicide," said Dr. James Veltmeyer. "We are dedicated to demonstrating to the world that suicide is not a choice but a disease."

"Ms. O'Connor approached us with the idea of forming a company named after her mother, Kathleen Campbell, who was a victim of suicide. I was impressed by Ms. O'Connor's deep insight into biology, as well as her unwavering commitment to help other people in her mother's situation," said Timothy Dixon, Chairman, President and CEO of Therapeutic Solutions International. "Having worked with Ms. O'Connor and after meeting certain milestones including establishment of two clinical trials, the board decided that enhanced value can be obtained with Campbell Neurosciences spinning out as a separate entity. We will support Ms. O'Connor and Campbell Neurosciences on an ongoing basis."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences
Three-Fold Increase in Inflammation Biomarker Observed in Patients with Suicidal Tendencies as Compared to Healthy Controls


https://www.prnewswire.com/news-release ... 07555.html


OCEANSIDE, Calif., Jan. 13, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from the Federally listed clinical trial "Correlation of Campbell Score with Suicidal Ideation."1

From a group of four healthy controls and four patients with suicidal ideations, the patients with suicidal ideations possessed approximately 3-fold higher levels of the inflammatory cytokine as compared to controls (24.2 ± 7.7 pg/ml vs 8.4 ±2.9 pg/ml).

The clinical trial is planned to recruit an additional 22 patients and aims to establish validity of the Campbell Score™ as an objective marker to quantify risk of suicide.

"Currently there are no objective means of knowing the true risk factor for a patient to kill themselves," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and Campbell Neurosciences. "We believe the Campbell Score™ is a first in class diagnostic tool which will not only prevent suicides but will be utilized as a tool for personalizing dosages of various psychiatric medicines and interventions."

The Campbell Score™ is currently being developed by Campbell Neurosciences, a partially-owned spinoff of Therapeutic Solutions International.

"More people die of suicide than in all the wars and natural disasters combined," said Kalina O'Connor, President and Chief Executive Officer of Campbell Neurosciences. "By bringing advanced immunological sciences to the area of psychiatry, we believe we can positively impact the only field of medicine that does not routinely interrogate the organ it is treating."

"Quite exciting to us as a Company is the fact that our nutraceutical product QuadraMune™, which is currently in clinical trials for prevention of COVID-19,2 has been demonstrated to reduce concentrations of the same inflammatory markers assessed in the Campbell Score™," said Famela Ramos, Vice President of Business Development for Therapeutic Solutions International. "We are eager to initiate clinical trials utilizing science-based nutraceutical approaches as mono-therapies or adjuvants to existing therapies in order to effectively reduce brain inflammation and inhibit suicidal thoughts."

"The expedience of the Campbell Team in conducting the ongoing trial is unparalleled," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "It is an honor to synergize with the work of Miss O'Connor and her team, who are dedicated to finding a cure to suicide using a regenerative psychiatry approach. Therapeutic Solutions International is an "Innovation Factory" with programs in cell therapy, immunology and nutraceuticals. Through working with Campbell Neurosciences, we provide broad and deep intellectual property while allowing Campbell Neurosciences to remain laser focused on their mission of "curing suicide."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Correlation of Campbell Score With Suicidal Ideation - Full Text View - ClinicalTrials.gov
2 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov

ir@tsoimail.com



https://c212.net/c/img/favicon.png?sn=A ... 2021-01-13 View original content:http://www.prnewswire.com/news-releases ... 07555.html

SOURCE Therapeutic Solutions International
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction

Company uses Blood Based Immune Test as "Stethoscope for the Brain"

"Suicide is a Disease, Not a Choice"


https://www.prnewswire.com/news-release ... 30996.html


ELK CITY, Idaho, Feb. 18, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today its spin-off company, Campbell Neurosciences Inc, successfully completed a 30-patient clinical trial assessing blood levels of an inflammatory cytokine as a predictor for suicidal ideation.

The clinical trial, which is registered on the Federal Clinical Trials website (#NCT04606875)1, assessed levels of inflammatory marker in 10 patients with no history of suicide (Group 1), 10 patients with suicidal ideations (Group 2), and 10 patients with suicidal ideations who attempted suicide in the last 6 months (Group 3). Results demonstrated that patients in Group 1 had 7.6±2.4 pg/ml of cytokine, whereas Group 2 had 28.9 ±6.3 pg/ml and in Group 3 had 45.8 ±7.7 pg/ml.

"This is the first step in the important journey to develop the first blood-based test for suicidal ideation" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The Campbell Score is named after my mother, Kathleen Campbell, who was a victim of suicide. These data support our original purpose for starting the Company, which is to prove that suicide is a disease and not a choice."

"The current data fits well into the paradigm that many mental illnesses possess an inflammatory component" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Miss O'Connor did an excellent job of summarizing existing clinical data supporting the association between inflammation and mental diseases in a pre-publication paper titled "Suicide: An Immunological Disorder?2" added Dr. Veltmeyer"

"By establishing a blood-based test, the Company aims to provide a new weapon for psychiatrists to use in their war against the second largest killer of young people between 15 to 34 years of age" said Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "As the parent company of Campbell Neurosciences, we have started discussions with various stakeholders in the mental health space with the idea of initiating wide-scale implementation of the Campbell Score."

"The interplay between the immune system and the brain has been known for a while but not acted upon in any significant manner until now" said Timothy Dixon, President and CEO of Therapeutic Solutions International. "As an immunotherapy company, we are proud at this initial success of our phase 2 clinical trial, because it preliminarily validates what we have been thinking all along: that the immune system can be used as a stethoscope for what is happening in the brain."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Correlation of Campbell Score With Suicidal Ideation - Full Text View - ClinicalTrials.gov

2 Suicide: An Immunological Disorder?
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™

Suicide Prevention Company Leverages Brain-Immune Connection to Tackle 54 Billion Dollar Gambling Addiction Epidemic


https://www.prnewswire.com/news-release ... 35601.html


ELK CITY, Idaho, Feb. 25, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from its ongoing Federally Registered clinical trial entitled "Validation of Kaihani Score for Gambling Addiction1".

Preliminary data revealed a profound increase in the neuromodulatory protein assessed by Kaihani Score™ which correlated with gambling addiction severity. Four patients with no gambling addiction had 13.4±1.6 ng/ml, four patients with moderate gambling addiction had 37.4±5.6 ng/ml, and four patients with several gambling addiction had 57.7±6.3 ng/ml. Severity of gambling addiction was assessed using Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS). The clinical study needs to recruit another 6 patients per group for completion.

"These preliminary results strongly support our overarching concept that the immune system can be utilized as a stethoscope for the brain" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "It is our aim at Campbell Neurosciences to elucidate the biological basis of mental illnesses, and using this knowledge to develop cures, not band-aid drugs."

Campbell Neurosciences, a spin-off of the biotherapeutics company Therapeutic Solutions International is named after Kathleen Campbell, mother of Kalina O'Connor, who was a victim of suicide.

"In contrast to the Campbell Score™, which assesses inflammatory markers as a means of diagnosing suicidal ideations, the Kaihani Score™ assesses specific neuromodulatory peptides made by the brains of gambling addicts" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "This completely different nature of the cytokines involved suggest the existence of complicated neuroimmune circuits. Our mission at Campbell is to decipher these circuits and develop practical interventions."

"This is a significant milestone in the treatment of gambling addiction, which is estimated according to economists to take a $54 billion annual toll on our economy2" stated Wais Kaihani, co-inventor of the Kaihani score and consultant to the Company.

"As a clinical stage cancer immunotherapy company, we see the potent effects of the immune system on the nervous system in our various preclinical and clinical studies" said Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Inventor of the Kaihani Score™. "Gambling addiction is a significant problem for which no medical interventions or even proper diagnosis exists. I congratulate Ms. O'Connor and her team for scientifically and expediently addressing this major affliction on our society."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Validation of Kaihani Score for Gambling Addiction - Full Text View - ClinicalTrials.gov
2 Social costs of gambling nearly half that of drug abuse, new book concludes | Archives | News Bureau | University of Illinois

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention

"First in Class" Therapy Reduces Suicide Associated Biological Pathways in Preclinical Studies


https://www.prnewswire.com/news-release ... 40517.html


ELK CITY, Idaho, March 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical results and filing of a patent covering the use of manipulated cord blood derived monocytes for prevention of suicidal ideations as well as inflammation of the brain. Company scientists found that administration of non-stem cell components of cord blood to mice exposed to brain inflammation resulted in protection of neurological function as well as suppression of immunological proteins associated in humans with suicidal thoughts.

Paradoxically, it was found that the monocyte component of cord blood was associated with therapeutic activity. Monocytes are typically inflammation inducing cells. Through a trial and error process, the Company found oxytocin pretreatment under proprietary conditions resulted in protection of neurological function (Morris Water Maze) and reduction of inflammation in preclinical studies.

"The fact that the fetus is not immunologically rejected by the mother, despite being genetically incompatible is still largely unexplained," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "We believe that these monocytes possess unique properties that stop the mother's immune system from rejecting the offspring. The data suggests that these same properties may be harnessed to stop inflammation of the brain, which predisposes to suicide."

"While great advances have been made in development of small molecule drugs, there is a growing appreciation for new cell therapies. A recent example is the >$150 million capital raise for a preclinical stage cellular immunotherapy company,1" stated Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "Given easy access to cord blood and economical cost of production, we are eager to continue our preclinical work and advance to FDA IND filing."

"Campbell Neurosciences recently announced positive results of our Campbell Score™ blood based suicidal propensity clinical trial," said Kalina O'Connor, President and Chief Executive Officer of Campbell Neurosciences. "Given that the inflammatory proteins that were reduced in preclinical studies are similar to those assessed by the Campbell Score™ in patients, we are optimistic about clinical translation of this novel approach to preventing suicide."

"The current data and patent filing exemplifies the synergistic relationship between us and our spin-off," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The discovery was facilitated by experimentation during production of StemVacs, our umbilical cord derived cancer vaccine. It was observed that monocytes, which are also used to produce immune stimulatory dendritic cells, can acquire radically different properties based on growth conditions which we control in a proprietary manner. We plan to collaborate closely for clinical translation of this unique approach to a psychiatric condition."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline (prnewswire.com)

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Efficacy of Kaihani Score in Prediction of Gambling Addiction

Suicide Prevention Company Succeeds in Utilizing Brain-Immune Connection to Quantifiably Assess Gambling Addiction Status


https://www.prnewswire.com/news-release ... 61934.html


ELK CITY, Idaho, April 5, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today completion of its 30-patient trial assessing the Kaihani Score blood-based test for gambling addiction.

The clinical trial, which as registered on the Federal Clinical Trials Database as Validation of Kaihani Score for Gambling Addiction1 showed a profound difference of a specific neuromodulatory protein between healthy controls (15.6±5.5 ng/ml), patients with moderate gambling addiction (34.8±11.2 ng/ml) and patients with severe gambling addiction (50.9±24.3 ng/ml). Severity of gambling addition was assessed using Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS).

"This data demonstrates the ability to assess psychological abnormalities using quantitative blood-based approaches" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "It is our aim at Campbell Neurosciences to address the root causes of mental illnesses, and using this knowledge to develop cures, not band-aid drugs."

Campbell Neurosciences, a spin-off of the biotherapeutics company Therapeutic Solutions International is named after Kathleen Campbell, mother of Kalina O'Connor, who was a victim of suicide.

"In contrast to the Campbell Score™, which assesses inflammatory markers as a means of diagnosing suicidal ideations, the Kaihani Score™ assesses specific neuromodulatory peptides made by the brains of gambling addicts" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "A completely different nature of the cytokines involved suggest the existence of complicated neuroimmune circuits. Our mission at Campbell is to decipher these circuits and develop practical interventions."

Ms. O'Connor recently published a manuscript outlining the contributions of the immune system to nervous system function with emphasis on mental illness Suicide: An Immunological Disorder?2

"The successful completion of this clinical trial indicates that we now have a potential new weapon in identifying who is at risk of gambling addition, which is the first step in conquering this epidemic which takes a $54 billion annual toll on our economy3" said Wais Kaihani, co-inventor of the Kaihani score and consultant to the Company.

"I congratulate Campbell Neurosciences and the excellent work their clinical team has performed in rapidly completing the second clinical trial this year demonstrating successful identification of mental illness using blood based immunological tests" stated Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Inventor of the Kaihani Score™.

The Company is currently engaging regulators in discussions with the aim of initiating a pivotal registration trial for both the Campbell Score and the Kaihani Score.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

1 Validation of Kaihani Score for Gambling Addiction
2 Suicide: An Immunological Disorder?
3 Social costs of gambling nearly half that of drug abuse, new book concludes

SOURCE Therapeutic Solutions International

Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction

Company Announces Second Therapeutic Candidate for Leveraging Regenerative and Immunological Approaches for Overcoming > $78.5 Billion Dollar Addiction Epidemic



https://www.prnewswire.com/news-release ... 67713.html


ELK CITY, Idaho, April 13, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction.

In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction. Administration of the Company's cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain.

"In recent times numerous publications have reported the link between brain inflammation and opioid addiction1,2" said Dr. James Veltmeyer, Chief Medical Officer of Campbell Neurosciences. "By combining the regenerative effects of umbilical cord blood, with the anti-inflammatory properties of NanoStilbeneä, together with proprietary neuromodulating agents, we have created a treatment approach which appears to be safe and potently effective in our preclinical studies."

"Campbell Neurosciences is focused not just on identifying suicidal ideations utilizing our clinically validated Campbell Score™ blood-based test, but also on providing possible solutions to prevent suicide," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The announcement of preclinical success using our cord blood based approach sets the foundation for optimization and development of a clinically-useful approach to treat this dreaded disease."

"Current approaches to drug addiction many times involve replacing one addiction with another one, while not addressing the root cause," said Timothy Dixon, President and CEO of Therapeutic Solutions International, the Parent Company of Campbell Neurosciences and co-inventor of the patent. "We are glad to lend our immunological expertise to Campbell Neurosciences for the development of the world's first immunotherapeutic approach to opioid addiction."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

1 Eidson et al. Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides. 2019 May;115:51-58.
2 Hofford et al. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci. 2019 Aug;50(3):2562-2573.

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2522
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Identifies Mechanism of Action for Umbilical Cord Blood Derived NarcoStem™ Drug Rehabilitation Product

Company Demonstrates Key Role for "Endogenous Nerve Repair Compound" in Mediating Therapeutic Activities of Novel Regenerative Approach



https://www.prnewswire.com/news-release ... 71379.html


ELK CITY, Idaho, April 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today data implicating a key role in the protein Brain Derived Neurotrophic Factor (BDNF) in the therapeutic activities of NarcoStem™, an umbilical cord blood derived biologic demonstrated to possess positive animal data in preclinical models of addiction and drug induced brain damaged.

"It is saddening that what many consider to be cutting edge approaches to treatment of drug addiction is simply replacement of one harmful drug with another drug," stated Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and Top Doctor of San Diego. "I am proud to work with TSOI and with Campbell Neurosciences at creating a therapy that concurrently reduces brain inflammation, suppresses addiction associated urges, while at the same time repairs damaged nerve tissue. This is not something that ketamine, CBD, or psilocybin are capable of doing. Demonstration that BDNF mediates therapeutic activities of NarcoStem™ helps accelerate the timeline for clinical translation of this inhalable therapeutic."

BDNF is considered a "master molecule" in controlling brain function and has been reported by numerous groups to associate with efficacy of anti-depressants, as well as the ability to overcome addictive tendencies. Unfortunately, it is almost impossible to provide recombinant BDNF directly into the brain due to its size and half live. Accordingly, preliminary data by the Company suggests that administration of NarcoStem™ can directly stimulate the brain to produce its own BDNF.

"The recent successes in obtaining positive clinical data for both the Campbell Score and the Kaihani Score pushes us to initiate creation of therapeutic approaches to actually intervene at suicidal ideations and conditions predisposing to these conditions," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "It is fundamentally important that we know the mechanisms of action for our products and we are extremely satisfied at the "Warp Speed" that our scientists have been working on to generate this exciting data."

"The staggering rise in drug addiction, as well as the disturbing news that as many as 1 out of 3 post-covid patients will suffer neurological manifestations, is very strong rationale for our 'hyper-acceleration,' in developing regenerative approaches to neurological issues," said Timothy Dixon, President and CEO of TSOI. "We look forward to continuing our collaborations with internationally renowned scientists dedicated to utilizing modern day approaches to solve this age-old curse of drug addiction."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
Post Reply